FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / csa-agreement-analysis-memo.docx
csa-agreement-analysis-memo.docx · 1018-00009

Parties

Harkness LLP
Agreement Between Penterra Pharmaceuticals Corp
Penterra Pharmaceuticals Corp
Associates LLP
Whitmore Valuation Group LLC
Penterra Manufacturing Ireland Ltd
Altera Corp
Harborview Corp

Dates

July 25, 2022
July 1, 2012
May 16, 2022
December 31, 2020
March 15, 2012
August 18, 2022
June 20, 2022
September 15, 2022
September 2, 2022

Amounts

$312
$235.01
$852
$6.82
$1.47
€2.14
€1.06
$3.12
$1.34
$1.87

Obligations

The regulations establish a detailed framework of requirements that must be satisfied for an arrangement to qualify as a CSA and to avoid adjustment by the IRS under IRC § 482
Each participant must be a controlled taxpayer within the meaning of Treas
482-1(i)(5), must reasonably anticipate benefits from exploitation of the cost-shared intangibles in its assigned territory, and must substantially comply with the provisions of the CSA
This provision establishes the requirement that each controlled participant's share of IDA costs must be proportional to its share of reasonably anticipated benefits from the cost-shared intangibles
482-7(b)(1) requires that each controlled participant in a CSA satisfy three conditions: (i) the participant must be a "controlled taxpayer" within the meaning of Treas
482-1(i)(5), meaning it must be one of two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests; (ii) the participant must "reasonably anticipate" deriving benefits from exploitation of the cost-shared intangibles in its assigned territory; and (iii) the participant must "substantially comply" with the material provisions of the CSA throughout the relevant period